TM38837 is a new small molecule inverse agonist/antagonist of the CB1cannabinoid receptor. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.
^Hung, M. S.; Chang, C. P.; Li, T. C.; Yeh, T. K.; Song, J. S.; Lin, Y.; Wu, C. H.; Kuo, P. C.; Amancha, P. K.; Wong, Y. C.; Hsiao, W. C.; Chao, Y. S.; Shia, K. S. (2010). "Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist". ChemMedChem5 (9): 1439–1443. doi:10.1002/cmdc.201000246. PMID20652930.edit